Graybug Vision’s ongoing Phase I/II trial or GB-102 (1 mg sunitinib) injection for wet age-related macular degeneration should produce initial six-month data in Q2 2018, Jeff Cleland, PhD, president & CEO said during the Company Showcase 3 session at OIS@AAO 2017. GB-102 is a multiple-receptor tyrosine kinase inhibitor dosed twice yearly via an extended-release depot. Graybug Vision’s patented technology that involves injection with a small-gauge needle has potential as a prodrug technology platform for treatment of glaucoma for not only control of intraocular pressure but also for neuroprotection, Dr. Cleland stated. The company expects a preliminary readout on safety and efficacy of the Phase I trial in Q4 2018, he said, with Phase II topline safety and efficacy results due in 2020. In glaucoma, Graybug Vision expects to initiate preclinical studies in Q1 2018 and file an IND and initiate Phase I/II trials in Q1 2019, Dr. Cleland added.